Current Trials

Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults with Treatment Resistant Depression
Sponsor: Navitor Pharmaceuticals, Inc.
Study Phase: 2
Study Sites: Approximately 35 sites are planned in the US.
Indication: Treatment Resistant Depression (TRD)
Primary Objective: To evaluate the efficacy of NV-5138 compared to placebo when administered to adults with TRD.